<DOC>
	<DOCNO>NCT00002028</DOCNO>
	<brief_summary>The objective treatment IND protocol make didanosine ( ddI ) available patient HIV infection ( suffer AIDS related complex ( ARC ) AIDS ) develop document intolerance zidovudine ( AZT ) enter Phase II ddI program due protocol exclusion geographic location .</brief_summary>
	<brief_title>A Treatment IND ( Investigational New Drug ) Protocol Use Videx ( 2',3'-Dideoxyinosine , ddI ) Patients With Acquired Immunodeficiency Syndrome ( AIDS ) AIDS- Related Complex ( ARC ) Who Are Intolerant Zidovudine ( Retrovir )</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>AIDS-Related Complex</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Concomitant medication treatment AIDS ARC ( include aerosolize pentamidine ) . Phenytoin , caution . Note : Extreme caution exercise use ddI patient receive concomitant therapy , particularly receive nucleoside ( e.g . ganciclovir ) , drug toxicity similar observe ddI ( list include concomitant medication section protocol ) , drug significant toxicity , include many drug use treatment major opportunistic infection . Patients must : Have diagnosis AIDS symptomatic , HIV positive , CD4 cell count &lt; 200 cells/mm3 . Be intolerant zidovudine ( AZT ) therapy . Not suitable study entry phase II didanosine ( ddI ) study reason inclusion exclusion criterion reason geographic location . Be able provide sign informed consent ( parent/guardian appropriate ) . Be available monthly followup take ddI . Meet baseline lab criterion within 14 day prior initial drug dosing . Note : Extreme caution exercise use ddI patient receive concomitant therapy , particularly receive nucleoside ( e.g. , ganciclovir ) , drug toxicity similar observe ddI ( list include concomitant medication section protocol ) , drug significant toxicity , include many drug use treatment major opportunistic infection . Caution also exercise patient intractable diarrhea patient follow lowsodium diet . Physicians care patient must perform clinical laboratory evaluation every 7 10 day first 2 month ddI therapy . All highrisk patient ( example , patient preexist disorder body system know adversely affected ddI , particularly history peripheral neuropathy , pancreatitis , seizure disorder , cardiac abnormality , gout , significant elevation liver function test result ) , must clinical laboratory evaluation perform every 10 day result submit BristolMyers Squibb case report form provide . Prior Medication : Allowed : Antiemetic medication . Required : Zidovudine ( AZT ) . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malignancy likely require chemotherapy first 3 month ddI treatment . Acute pancreatitis . A poorly control seizure disorder . Grade B great peripheral neuropathy . Concurrent Medication : Excluded : Zidovudine ( AZT ) . Chemotherapy first 3 month ddI treatment . Patients follow exclude : Malignancy likely require systemic chemotherapy first 3 month ddI treatment . Acute pancreatitis . A poorly control seizure disorder . Grade B great peripheral neuropathy . Prior Medication : Excluded within 15 day study entry : Any antiretroviral drug except zidovudine ( AZT ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drugs , Investigational</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>